George Jay Goldsmith Sells 9,621 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock

COMPASS Pathways plc (NASDAQ:CMPS) major shareholder George Jay Goldsmith sold 9,621 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $8.29, for a total transaction of $79,758.09. Following the completion of the sale, the insider now owns 3,966,052 shares of the company’s stock, valued at $32,878,571.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

George Jay Goldsmith also recently made the following trade(s):

• On Tuesday, April 16th, George Jay Goldsmith sold 23,881 shares of COMPASS Pathways stock. The shares were sold at an average price of $8.53, for a total value of $203,704.93.
• On Monday, April 1st, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.96, for a total value of $230,720.00.
• On Tuesday, March 12th, George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock. The stock was sold at an average price of $10.58, for a total transaction of $166,529.20.

COMPASS Pathways Trading Down 0.8 %

Shares of NASDAQ CMPS opened at $8.54 on Wednesday. The company has a market cap of $528.97 million, a PE ratio of -3.57 and a beta of 2.39. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. The firm’s 50 day moving average price is $9.46 and its 200-day moving average price is $8.53. COMPASS Pathways plc has a 52-week low of $5.01 and a 52-week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.16). On average, equities research analysts expect that COMPASS Pathways plc will post -2.4 EPS for the current fiscal year.

Analysts Set New Price Targets

CMPS has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a research note on Tuesday, April 30th. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, March 1st. Finally, Morgan Stanley assumed coverage on COMPASS Pathways in a research note on Monday, April 1st. They set an “overweight” rating and a $30.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, COMPASS Pathways presently has a consensus rating of “Buy” and a consensus target price of $47.40.

Institutional Investors Weigh In On COMPASS Pathways

Several large investors have recently bought and sold shares of the business. Quest Partners LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $33,000. Bailard Inc. bought a new position in COMPASS Pathways during the third quarter valued at approximately $88,000. Conservest Capital Advisors Inc. purchased a new stake in COMPASS Pathways in the fourth quarter worth approximately $91,000. TAP Consulting LLC grew its position in COMPASS Pathways by 14.7% in the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after purchasing an additional 1,645 shares during the period. Finally, EWA LLC purchased a new stake in COMPASS Pathways during the 4th quarter valued at $107,000. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.